Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications.
Study Goal
The researchers aimed to review the impact of melatonin, among other hormones, on the pathophysiology, severity, and comorbid mental disorders in multiple sclerosis (MS).
Results Summary
The abstract mentions melatonin as one of the hormonal components discussed in the context of MS, but specific findings about its effects are not detailed. The focus is on its role in immune dysregulation and disease severity.
Population
Patients with multiple sclerosis (MS).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
glucocorticoids | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #1 |
estrogens | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #2 |
prolactin | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #3 |
dehydroepiandrosterone | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #4 |
melatonin | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #5 |
vitamin D | neutral | immune dysregulation, psychology, and cognitive status | patients with MS | - | have a great impact | #6 |
glucocorticoids | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #7 |
estrogens | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #8 |
prolactin | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #9 |
dehydroepiandrosterone | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #10 |
melatonin | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #11 |
vitamin D | neutral | fertility and response to treatment | patients with MS | - | have a great impact | #12 |
glucocorticoids | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #13 |
estrogens | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #14 |
prolactin | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #15 |
dehydroepiandrosterone | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #16 |
melatonin | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #17 |
vitamin D | neutral | MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility | - | - | impact | #18 |
Multiple sclerosis (MS) is a multifactorial, chronic, immune-mediated, and neurodegenerative disease, having a well-known hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Several hormones have a great impact in the immune dysregulation, psychology, and cognitive status of patients with MS, as also in the fertility and response to treatment. In this comprehensive review, as an introduction, we mention basic data concerning MS: epidemiology, genetics, immunogenetics, epigenetics, pathophysiology, and neuroimmunology. Hormonal components of the disease cascade, mainly glucocorticoids (stress-related hormone), estrogens, prolactin and dehydroepiandrosterone (sex-related hormones), melatonin, and vitamin D, are discussed, aiming at focusing on core data regarding the impact of these hormones in MS pathophysiology, severity of the disease, correlation with comorbid mental disorders, and fertility. A great focus is given in the pre- and post-pregnancy period of MS patients, in the context of the disease-modifying treatments (DMTs) and HPA status, having in mind that there are only very limited knowledge and few papers on this specific life period of these women, having MS. All this data are presented in the main text and also in the workable tables, for the first time, suggesting targeted topics that need to be addressed in the near future.